- Argentina
- Finland
- Japan
- Senegal
- France
- Korea
- Slovakia
- Australia
- Germany
- Malaysia/Singapore
- South Africa
- Austria
- Greece
- Mexico
- Spain
- Belgium
- Hong Kong
- Netherlands
- Sweden
- Brazil
- Hungary
- New Zealand
- Switzerland
- Canada
- India
- Norway
- Taiwan
- China
- Indonesia
- Pakistan
- Thailand
- Colombia
- Ireland
- Philippines
- Turkey
- Czech Republic
- Israel
- Poland
- United Kingdom
- Denmark
- Italy
- Portugal
- Venezuela
Pfizer Joins Academic-Industry Collaboration for Autism Drug Discovery
Pfizer is one of the key partners in a newly launched international consortium of scientists that represents one of the largest ever academic-industry research collaborations aimed at finding new methods for the development of drugs for autism spectrum disorders.
Product Pipeline
Our pipeline of new medicines in development focuses on a broad range of unmet medical needs.
About R&D
How research at Pfizer works, from the various phases of research to clinical trials to post-marketing commitments.
Ethical Research and Trials
Pfizer works to discover and develop innovative, safe, and effective ways to prevent or treat some of the world's most challenging diseases.
Post-Marketing Commitments
Information on how post marketing commitment studies are conducted, as well as status information for products in the U.S. and EU.
Partnering with Pfizer
Through partnerships, alliances, licensing and venture investments, Pfizer recognizes collaboration with other organizations as essential to success.
Meet some of Pfizer's most inspiring science and medical professionals.
Read Pfizer's commitment to conducting ethical research, ensuring the safety and privacy of patients and how we approach clinical trials.